Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Bloedleukocytenprofilering bij eosinofiel type 2 astma: invloed van systemische IL-5-targeting

10 augustus 2026 bijgewerkt door: Region Skane

The goal of this exploratory and observational prospective study is to study the composition and phenotypes of blood leukocytes collected from asthmatic patients before and after instantiated treatment with the interleukin-5 neutralizing antibody mepolizumab. Comparisons will be made to leukocyte profiles in patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.

Studie Overzicht

Gedetailleerde beschrijving

Asthma is a chronic inflammatory and obstructive condition affecting the airways. The disease is commonly associated with elevated blood eosinophils and tissue eosinophilia. Many aspects of the pathophysiological mechanisms and clinical symptoms are controlled by conventional therapies such as inhaled corticosteroids (ICS) and long acting β2 agonists. However, some patients remain clinically uncontrolled and need additional treatment such as direct targeting of eosinophil granulocytes by neutralizing the eosinophil-promoting cytokine interleukin 5 (IL5). Mepolizumab is a humanized monoclonal IL-5 neutralizing antibody that is used to treat patients with moderate-severe eosinophilic asthma. While a marked reduction of eosinophils is a key effect of mepolizumab, the exact mechanism of action is unknown. Apart from basophils, that also express the receptor for IL-5, other leukocytes are likely to be indirectly affected by the suppressed eosinophilia. In addition, it is largely unknown to what extent the few eosinophils remaining after anti-IL5 treatment differ from pre-treatment eosinophils.

The present study is a prospective observational asthma study that aims to use microscopic analysis to investigate the composition and subtypes of blood leukocytes collected before and after instantiated mepolizumab treatment. Comparisons are made to patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.

Studietype

Observationeel

Inschrijving (Werkelijk)

37

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Skåne County
      • Lund, Skåne County, Zweden, 22185
        • The Lung and Allergy Clinic, Skåne University Hospital (SUS)

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

All asthma patients will be recruited at the Department of Allergology and Lung Medicine, Skåne University Hospital (SUS), Lund, Sweden. Healthy control subjects are recruited by local advertisement.

Beschrijving

Inclusion Criteria:

  • Clinical diagnosis of asthma (the asthma patient arms)
  • Eligible for Mepolizumab treatment as per the country-specific prescribing information (the arms with Mepolizumab)

Exclusion criteria:

  • Any diagnosed infection (all arms)
  • Previous history of lung disease, chronic inflammatory condition, atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling (Healthy non-asthma control subjects)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: CROSS_SECTIONAL

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Asthma patients initiating Mepolizumab treatment

Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection

Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.

Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Andere namen:
  • Mepolizumab (merknaam: Nucala)

Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Andere namen:
  • ICS en LABA
Asthma patients already on Mepolizumab treatment

Patients that have been selected and given Mepolizumab treatment for > 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for > 4 weeks will be included. Exclusion criteria: any infections

Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.

Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Andere namen:
  • Mepolizumab (merknaam: Nucala)

Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Andere namen:
  • ICS en LABA
Asthma patients without Mepolizumab treatment

Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections

Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Andere namen:
  • ICS en LABA
Healthy non-asthmatic control subjects

Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Blood Eosinophil Marker Expression
Tijdsspanne: Baseline, Day 2, and Month 4 after mepolizumab initiation

Quantitative analysis of low-intensity proMBP-positive eosinophil-lineage proxy cells in FFPE blood leukocyte pellet sections

Baseline, Day 2, and Month 4 after mepolizumab initiation
Change in Blood Basophil Marker Expression
Tijdsspanne: Baseline, Day 2, and Month 4 after mepolizumab initiation

Quantitative analysis of high-intensity proMBP-positive basophil-like cells in FFPE blood leukocyte pellet sections.

Baseline, Day 2, and Month 4 after mepolizumab initiation
Change in Blood Leukocyte Composition
Tijdsspanne: Baseline, Day 2, and Month 4 after mepolizumab initiation

Relative proportion of low-/mid-intensity proMBP-positive eosinophil-lineage proxy cells within the proMBP panel in FFPE blood leukocyte pellet sections

Baseline, Day 2, and Month 4 after mepolizumab initiation

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Blood T Lymphocyte Marker Expression
Tijdsspanne: Baseline, Day 2, and Month 4 after mepolizumab initiation

Quantitative CD4 Th-axis balance readout in FFPE blood leukocyte pellet sections, expressed as log2(GATA3/T-bet ratio).

Baseline, Day 2, and Month 4 after mepolizumab initiation
Change in Blood B Lymphocyte Marker Expression
Tijdsspanne: Baseline, Day 2, and Month 4 after mepolizumab initiation

Quantitative B-cell HLA-DR readout in FFPE blood leukocyte pellet sections, expressed as the percentage of HLA-DR-positive cells within the CD19/CD20-gated population.

Baseline, Day 2, and Month 4 after mepolizumab initiation
Leukocyte Total Cell Counts
Tijdsspanne: Baseline, Day 2, and Month 4 after mepolizumab initiation.

Routine clinical laboratory total leukocyte counts in peripheral blood

Baseline, Day 2, and Month 4 after mepolizumab initiation.

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Forced Expiratory Volume in 1 Second (FEV1)
Tijdsspanne: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.

Spirometry: Forced Expiratory Volume, 1s; (FEV1).

Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
Change in Forced Vital Capacity (FVC)
Tijdsspanne: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.

Spirometry: Forced Vital Capacity (FVC)

Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
Change in Exhaled FeNo
Tijdsspanne: Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.

Fractional exhaled NO will be measured at multiple flows

Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Jonas Erjefält, Lund University Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 januari 2019

Primaire voltooiing (Werkelijk)

1 september 2025

Studie voltooiing (Werkelijk)

18 december 2025

Studieregistratiedata

Eerst ingediend

15 december 2022

Eerst ingediend dat voldeed aan de QC-criteria

16 januari 2023

Eerst geplaatst (Werkelijk)

19 januari 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 augustus 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren